Preclinical Model Strategies for T-Cell Engagers: From Oncology to Autoimmune Disease

T-cell engagers (TCEs) are being explored across a growing range of therapeutic applications, from oncology to autoimmune disease. While the same TCE modality can be pursued across indications, differences in disease biology, target cell populations, and therapeutic objectives can lead to different preclinical strategies.

Join GemPharmatech’s oncology and autoimmune teams for a practical discussion of preclinical model strategies for TCE programs. The session will examine how model selection and evaluation endpoints can be tailored to different therapeutic contexts, from tumor-targeted T-cell engagement and in vivo antitumor efficacy to immune-cell depletion and safety evaluation in autoimmune disease.

The webinar will conclude with a case-based cross-talk between the oncology and autoimmune teams, exploring how preclinical strategies may differ when the same target is evaluated across indications, how cytokine-related safety signals, including CRS, can be evaluated, and how dosing strategy and exposure can influence study design.

In this webinar, you will learn:

• How to select appropriate preclinical models for TCE programs across oncology and autoimmune disease

• Which efficacy and safety endpoints to evaluate, from T-cell engagement and tumor killing to B-cell depletion, immune reconstitution, and cytokine-related signals

• How therapeutic context influences study design, including target biology, dosing strategy, and exposure considerations

• Practical insights from representative models and data to support preclinical decision-making in TCE development

Date: Tuesday, October 27, 2026

Time: 8:00 AM PDT | 10:00 AM CDT | 11:00 AM EDT | 4:00 PM CET

Speaker: Dr. Wanjun Yuan from Oncology Pipeline & Dr. Haiqiao Sun from Autoimmune Pipeline